Company Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Presented New Clinical and Pre-Clinical Data at American College of Cardiology Meeting

Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced two posters presented yesterday at the annual meeting of the American College of Cardiology (ACC). This research adds to the growing body of clinical and pre-clinical data relevant to the use of EPA with statins.

The first poster, “Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-Treated Patients With Elevated Cardiovascular Risk and Very High Triglyceride Levels: Results From the MARINE Study,” is an exploratory subgroup analysis of results from Amarin’sMARINE trial of Vascepa® (icosapent ethyl) and observed that, compared to placebo in statin-treated patients with elevated cardiovascular risk and very high triglycerides (TGs), Vascepa administered at 4 g/day significantly lowered TGs and improved other parameters relevant to cardiovascular health without raising LDL (“bad”) cholesterol. The MARINE study and this subgroup analysis were led by Harold Bays, MD, Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center,Louisville, KY.

The second poster, a pre-clinical study titled, “Eicosapentaenoic Acid and Atorvastatin Active Metabolite, Alone or in Combination, Reversed Glucose- and Oxidized LDL-Induced Endothelial Dysfunction Measured Ex Vivo in Rats,” noted that, independently and in combination, EPA and the active metabolite of atorvastatin improved endothelial function measured in rat kidney sections. This pre-clinical research was led by R. Preston Mason, Ph.D., Department of Medicine, Division of Cardiology, Brigham & Women’s Hospital, Harvard Medical School, and president and founder, Elucida Research LLC.

“The results of these two studies add to the growing body of clinical and pre-clinical data on the effects of EPA when combined with statins under the conditions studied,” said Steven Ketchum, Ph.D., president of research and development and chief scientific officer at Amarin. “Amarin’s REDUCE-IT trial, examining the effect of EPA therapy on top of statin therapy in at-risk patients with elevated triglycerides has reached target enrollment and will provide needed cardiovascular outcomes data for this important patient population.” (Original Source)

Shares of Amarin Corporation closed last Friday at $1.58, up $0.05 or 3.27%. AMRN has a 1-year high of $2.80 and a 1-year low of $1.24. The stock’s 50-day moving average is $1.48 and its 200-day moving average is $1.76.

On the ratings front, Amarin has been the subject of a number of recent research reports. In a report issued on February 26, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AMRN, with a price target of $10, which implies an upside of 532.9% from current levels. Separately, on December 9, Oppenheimer’s Akiva Felt assigned a Hold rating to the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Andrew Fein and Akiva Felt have a total average return of 3.6% and -0.1% respectively. Fein has a success rate of 44.9% and is ranked #858 out of 3775 analysts, while Felt has a success rate of 34.3% and is ranked #2488.

Amarin Corp. Plc is a biopharmaceutical company, which engages in the commercialization and development of therapeutics to improve cardiovascular health. Its product, Vascepa capsules, is use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts